Treatment of hepatitis C in HIV patients in the new era of direct-acting antivirals

被引：3
作者：
Fernández-Montero J.V. [1 ]
Vispo E. [1 ]
Barreiro P. [1 ]
De Mendoza C. [1 ]
Labarga P. [1 ]
Soriano V. [1 ]
机构：
[1] Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid
来源：
Current Hepatitis Reports | 2013年 / 12卷 / 4期
关键词：
Antiviral therapy; Boceprevir; Coinfection; Faldaprevir; Hepatitis C; HIV; Simeprevir; Sofosbuvir; Telaprevir;
D O I：
10.1007/s11901-013-0179-1
中图分类号：
学科分类号：
摘要：
Chronic hepatitis C virus (HCV) infection occurs globally in 20 % of HIV-seropositive patients. In coinfected individuals, HCV-related liver disease is a leading cause of morbidity and mortality. The advent of new direct-acting antivirals (DAA) has been particularly awaited for this population, in whom treatment with peginterferon plus ribavirin depicts limited efficacy and poor tolerability. However, pharmacologic interactions, drug resistance, medication adherence and pricing are major challenges using DAA in HIV/HCVcoinfected patients. Moreover, if the benefit of new antiviral therapies for hepatitis C wants to be recognized at population scale, underdiagnosis and access to particularly difficult to reach populations must be ensured. © Springer Science+Business Media New York 2013.
引用
收藏
页码：269 / 275
页数：6
相关论文
共 79 条
[1]  
Palella F., Baker R., Moorman A., Et al., Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIVoutpatient study, J Acquir Immune Defic Syndr, 43, pp. 27-34, (2006)
[2]  
Weber R., Sabin C., Friis-Moller N., Et al., Liver-related deaths in persons infected with the HIV: The D:A:D study, Arch Intern Med, 166, pp. 1632-1641, (2006)
[3]  
Wyatt C., Malvestutto C., Coca S., Et al., The impact of hepatitis C virus coinfection on HIV-related kidney disease: A systematic review and meta-analysis, AIDS, 22, pp. 1799-1807, (2008)
[4]  
Peters L., Grint D., Lundgren J., Et al., HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients, AIDS, 26, pp. 1917-1926, (2012)
[5]  
Kakinami L., Block R., Adams M., Cohn S., Maliakkal B., Fisher S., Risk of cardiovascular disease in HIV, hepatitis C or HIV/HCV patients compared to the general population, Int J Clin Pract, 67, pp. 6-13, (2013)
[6]  
Lo Re V., Teal V., Localio A., Et al., Risk of hip fracture associated with HCV infection and HCV/HIV coinfection, Hepatology, 56, pp. 1688-1698, (2012)
[7]  
Soriano V., Vispo E., Fernandez-Montero J.V., Labarga P., Barreiro P., Update on HIV/HCV coinfection, Curr HIV/AIDS Rep, (2013)
[8]  
Soriano V., Sherman K., Rockstroh J., Et al., Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients, AIDS, 25, pp. 2197-2208, (2011)
[9]  
Naggie S., Sulkowski M., Management of patients coinfected with HCV and HIV: A close look at the role for direct-acting antivirals, Gastroenterology, 142, pp. 1324-1334, (2012)
[10]  
Barreiro P., Vispo E., Labarga P., Et al., Management and treatment of chronic hepatitis C in HIV patients, Semin Liver Dis, 32, pp. 138-146, (2012)
12345678